<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oral Cancer News &#187; head and neck cancer</title>
	<atom:link href="http://oralcancernews.org/wp/tag/head-and-neck-cancer/feed/" rel="self" type="application/rss+xml" />
	<link>http://oralcancernews.org/wp</link>
	<description>The Oral Cancer Foundation News Archive</description>
	<lastBuildDate>Mon, 06 Feb 2012 22:09:34 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Head and neck cancer carries substantial comorbidity burden</title>
		<link>http://oralcancernews.org/wp/head-and-neck-cancer-carries-substantial-comorbidity-burden/</link>
		<comments>http://oralcancernews.org/wp/head-and-neck-cancer-carries-substantial-comorbidity-burden/#comments</comments>
		<pubDate>Mon, 06 Feb 2012 17:16:32 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[comorbidity]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[oral cavity]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12428</guid>
		<description><![CDATA[Source: MedWire News People with head and neck cancer experience a high burden of both acute and chronic comorbidity, shows an analysis of a large Dutch population-based cohort. The researchers therefore advise clinicians to account for patients&#8217; comorbidity burden when assessing the risk-benefit profile for different treatment options. Sarah Landis (GlaxoSmithKline, London, UK) and co-workers [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/head-and-neck-cancer-carries-substantial-comorbidity-burden/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Newer radiation technology improves head and neck cancer patients&#8217; long-term quality of life</title>
		<link>http://oralcancernews.org/wp/newer-radiation-technology-improves-head-and-neck-cancer-patients-long-term-quality-of-life/</link>
		<comments>http://oralcancernews.org/wp/newer-radiation-technology-improves-head-and-neck-cancer-patients-long-term-quality-of-life/#comments</comments>
		<pubDate>Fri, 27 Jan 2012 18:28:22 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[American Head and Neck Society]]></category>
		<category><![CDATA[American Society for Radiation Oncology]]></category>
		<category><![CDATA[American Society of clinical oncology]]></category>
		<category><![CDATA[dry mouth]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[IMRT]]></category>
		<category><![CDATA[Multidisciplinary Head and Neck Cancer Symposium]]></category>
		<category><![CDATA[radiation therapy]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12375</guid>
		<description><![CDATA[Source: Eurekalert.org Patients treated with IMRT for head and neck cancer report an increasingly better quality of life post-treatment when compared to patients receiving other forms of radiation therapy, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM. Intensity modulated radiation therapy, or IMRT, [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/newer-radiation-technology-improves-head-and-neck-cancer-patients-long-term-quality-of-life/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Grape seed extract kills head and neck cancer cells, leaves healthy cells unharmed</title>
		<link>http://oralcancernews.org/wp/grape-seed-extract-kills-head-and-neck-cancer-cells-leaves-healthy-cells-unharmed/</link>
		<comments>http://oralcancernews.org/wp/grape-seed-extract-kills-head-and-neck-cancer-cells-leaves-healthy-cells-unharmed/#comments</comments>
		<pubDate>Fri, 27 Jan 2012 18:15:04 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cancer cells]]></category>
		<category><![CDATA[grape seed extract]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[head and neck squamous cell carcinoma cells]]></category>
		<category><![CDATA[National Cancer Institute]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12369</guid>
		<description><![CDATA[Source: Colorado Cancer Blog Nearly 12,000 people will die of head and neck cancer in the United States this year and worldwide cases will exceed half a million. A study published this week in the journal Carcinogenesis shows that in both cell lines and mouse models, grape seed extract (GSE) kills head and neck squamous [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/grape-seed-extract-kills-head-and-neck-cancer-cells-leaves-healthy-cells-unharmed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oral temperature changes in head and neck cancer patients predicts   side effect severity</title>
		<link>http://oralcancernews.org/wp/oral-temperature-changes-in-head-and-neck-cancer-patients-predicts-side-effect-severity/</link>
		<comments>http://oralcancernews.org/wp/oral-temperature-changes-in-head-and-neck-cancer-patients-predicts-side-effect-severity/#comments</comments>
		<pubDate>Thu, 26 Jan 2012 22:32:36 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[ASCO]]></category>
		<category><![CDATA[ASTRO]]></category>
		<category><![CDATA[chemoreadiotherapy]]></category>
		<category><![CDATA[early detection]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[mucositis]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12363</guid>
		<description><![CDATA[Source: American Society for Radiation Oncology The abstract, &#8220;Pilot study of functional infrared imaging for early  detection of mucositis in locally advanced head and neck cancer  reated with chemoradiotherapy,&#8221; will be presented at the Head and  neck Society Meeting in Arizona today. This is a synopsis of that  presentation. Slight temperature increases of the oral mucus [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/oral-temperature-changes-in-head-and-neck-cancer-patients-predicts-side-effect-severity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oral Sex Cancer Virus More Common in Men Than Women, Study Finds</title>
		<link>http://oralcancernews.org/wp/oral-sex-cancer-virus-more-common-in-men-than-women-study-finds/</link>
		<comments>http://oralcancernews.org/wp/oral-sex-cancer-virus-more-common-in-men-than-women-study-finds/#comments</comments>
		<pubDate>Thu, 26 Jan 2012 17:10:18 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Centers for Disease Control and Prevention]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[human papillomavirus]]></category>
		<category><![CDATA[Journal of the American Medical Association]]></category>
		<category><![CDATA[oral sex]]></category>
		<category><![CDATA[sexually transmitted virus]]></category>
		<category><![CDATA[throat cancer]]></category>
		<category><![CDATA[vaccine]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12361</guid>
		<description><![CDATA[Source: Bloomberg.com About 10 percent of men and 3.6 percent of women are orally infected with human papillomavirus, which is acquired through oral sex and can cause cancer. There are two peaks in the age people are infected &#8212; 30 to 34 and 60 to 64, according to the study published today in the Journal [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/oral-sex-cancer-virus-more-common-in-men-than-women-study-finds/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fatal Infusion Reactions to Cetuximab: Role of Immunoglobulin E–Mediated Anaphylaxis</title>
		<link>http://oralcancernews.org/wp/fatal-infusion-reactions-to-cetuximab-role-of-immunoglobulin-e-mediated-anaphylaxis/</link>
		<comments>http://oralcancernews.org/wp/fatal-infusion-reactions-to-cetuximab-role-of-immunoglobulin-e-mediated-anaphylaxis/#comments</comments>
		<pubDate>Thu, 19 Jan 2012 17:24:57 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[colon cancer]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[Journal of Clinical Oncology]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12330</guid>
		<description><![CDATA[Source: Journal of Clinical Oncology To the Editor: In Journal of Clinical Oncology, Tronconi et al1 report a fatal hypersensitivity reaction to cetuximab in a 63-year-old patient with metastatic colon cancer and outlined a 0.1% incidence of death in the literature. We greatly acknowledge the authors&#8217; desire to communicate the risk of fatal anaphylactic reaction [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/fatal-infusion-reactions-to-cetuximab-role-of-immunoglobulin-e-mediated-anaphylaxis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Many Head and Neck Cancer Survivors Face Eating Problems</title>
		<link>http://oralcancernews.org/wp/many-head-and-neck-cancer-survivors-face-eating-problems/</link>
		<comments>http://oralcancernews.org/wp/many-head-and-neck-cancer-survivors-face-eating-problems/#comments</comments>
		<pubDate>Tue, 17 Jan 2012 17:17:50 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[dental problems]]></category>
		<category><![CDATA[depression]]></category>
		<category><![CDATA[eating issues]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[Pain]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12317</guid>
		<description><![CDATA[Source: HealthDay News Persistent pain, eating problems and depression are the most common problems experienced by long-term survivors of head and neck cancer, a new study finds. In the study, published in the Jan. 16 online issue of the journal Archives of Otolaryngology &#8212; Head &#38;amp; Neck Surgery, researchers looked at 337 people who were [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/many-head-and-neck-cancer-survivors-face-eating-problems/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Review Finds Evidence Lacking for Dry Mouth Remedies</title>
		<link>http://oralcancernews.org/wp/review-finds-evidence-lacking-for-dry-mouth-remedies/</link>
		<comments>http://oralcancernews.org/wp/review-finds-evidence-lacking-for-dry-mouth-remedies/#comments</comments>
		<pubDate>Wed, 28 Dec 2011 22:56:36 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[Biotene]]></category>
		<category><![CDATA[Carolinas Medical Center]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[xerostomia]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12245</guid>
		<description><![CDATA[Source: Medscape Today December 28, 2011 — There is not enough evidence to recommend any topical therapies for dry mouth, but that does not mean that they do not work, according to investigators who published a review of research on the therapies online December 4 in the Cochrane Library. &#8220;There was very little evidence,&#8221; said [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/review-finds-evidence-lacking-for-dry-mouth-remedies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quality-of-Life Outcomes in Transoral Robotic Surgery</title>
		<link>http://oralcancernews.org/wp/quality-of-life-outcomes-in-transoral-robotic-surgery/</link>
		<comments>http://oralcancernews.org/wp/quality-of-life-outcomes-in-transoral-robotic-surgery/#comments</comments>
		<pubDate>Tue, 27 Dec 2011 17:58:43 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[radiation therapy]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>
		<category><![CDATA[TORS]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12227</guid>
		<description><![CDATA[Source: SAGE Journals Online Abstract Objective. To report long-term, health-related quality-of-life (HRQOL) outcomes in patients treated with transoral robotic surgery (TORS). Study Design. Prospective, longitudinal, clinical study on functional and HRQOL outcomes in TORS. Setting. University tertiary care facility. Subjects and Methods. Patients who underwent TORS were asked to complete a Head and Neck Cancer [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/quality-of-life-outcomes-in-transoral-robotic-surgery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Planned Neck Dissection is Not Necessary in All Patients with N2-3 Head-and-Neck Cancer After Sequential Chemoradiotherapy</title>
		<link>http://oralcancernews.org/wp/a-planned-neck-dissection-is-not-necessary-in-all-patients-with-n2-3-head-and-neck-cancer-after-sequential-chemoradiotherapy/</link>
		<comments>http://oralcancernews.org/wp/a-planned-neck-dissection-is-not-necessary-in-all-patients-with-n2-3-head-and-neck-cancer-after-sequential-chemoradiotherapy/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 17:52:02 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[chemoradiotherapy]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[Head and neck squamous cell carcinoma]]></category>
		<category><![CDATA[planned neck dissection]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12198</guid>
		<description><![CDATA[Source: DocGuide.com PURPOSE: To assess the role of a planned neck dissection (PND) after sequential chemoradiotherapy for patients with head-and-neck cancer with N2-N3 nodal disease. METHODS AND MATERIALS: We reviewed 90 patients with N2-N3 head-and-neck squamous cell carcinoma treated between 1991 and 2001 on two sequential chemoradiotherapy protocols. All patients received induction and concurrent chemotherapy [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/a-planned-neck-dissection-is-not-necessary-in-all-patients-with-n2-3-head-and-neck-cancer-after-sequential-chemoradiotherapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UI professors: HPV editorial misses the mark</title>
		<link>http://oralcancernews.org/wp/ui-professors-hpv-editorial-misses-the-mark/</link>
		<comments>http://oralcancernews.org/wp/ui-professors-hpv-editorial-misses-the-mark/#comments</comments>
		<pubDate>Thu, 08 Dec 2011 17:31:17 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[cervical cancer]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[HPV vaccines]]></category>
		<category><![CDATA[Pap smears]]></category>
		<category><![CDATA[radiation]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12177</guid>
		<description><![CDATA[Source: The Daily Iowan The Nov. 29 editorial &#8220;Recommend Pap smears, not vaccines, to prevent cervical cancer&#8221; completely missed the mark with regard to HPV vaccines. We are researchers and clinicians at the University of Iowa who study and treat HPV and other infectious diseases. It is disturbing to think that the article might dissuade [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/ui-professors-hpv-editorial-misses-the-mark/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Lymphedema Common After Head and Neck Cancer</title>
		<link>http://oralcancernews.org/wp/lymphedema-common-after-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/lymphedema-common-after-head-and-neck-cancer/#comments</comments>
		<pubDate>Tue, 06 Dec 2011 17:29:30 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[lymphedema]]></category>
		<category><![CDATA[radiation therapy]]></category>
		<category><![CDATA[Vanderbilt University]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12167</guid>
		<description><![CDATA[Source: Elsevier Global Medical News &#160; SAN FRANCISCO (EGMN) &#8211; Lymphedema is highly common and a source of considerable morbidity among patients who undergo treatment for head and neck cancer, finds a cross-sectional study among 103 survivors. Fully three-fourths had developed some degree of lymphedema, according to results presented at the annual Oncology Congress presented [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/lymphedema-common-after-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Predictors of survival in mucosal melanoma of the head and neck.</title>
		<link>http://oralcancernews.org/wp/predictors-of-survival-in-mucosal-melanoma-of-the-head-and-neck/</link>
		<comments>http://oralcancernews.org/wp/predictors-of-survival-in-mucosal-melanoma-of-the-head-and-neck/#comments</comments>
		<pubDate>Tue, 15 Nov 2011 01:04:18 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[mucosal melanoma]]></category>
		<category><![CDATA[oral cavity]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12072</guid>
		<description><![CDATA[Source:MedScape.com Jethanamest D; Vila PM; Sikora AG; Morris LG Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, NY, USA. BACKGROUND: The head and neck is the most common site of mucosal melanoma, a cancer with poor prognosis. In contrast to cutaneous melanoma, mucosal melanoma of the head and neck (MMHN) is uncommon, with [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/predictors-of-survival-in-mucosal-melanoma-of-the-head-and-neck/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Although Most Smokers Want to Quit&#8230; Only a Fraction Actually Do</title>
		<link>http://oralcancernews.org/wp/although-most-smokers-want-to-quit-only-a-fraction-actually-do/</link>
		<comments>http://oralcancernews.org/wp/although-most-smokers-want-to-quit-only-a-fraction-actually-do/#comments</comments>
		<pubDate>Fri, 11 Nov 2011 22:22:32 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[health]]></category>
		<category><![CDATA[mouth cancer]]></category>
		<category><![CDATA[oral cancer]]></category>
		<category><![CDATA[smokers]]></category>
		<category><![CDATA[smoking]]></category>
		<category><![CDATA[throat cancer]]></category>
		<category><![CDATA[WSJ]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12070</guid>
		<description><![CDATA[Source: The Wall Street Journal Author: Betsy McKay &#160; More than two-thirds of American smokers want to quit, but only a fraction actually do, underscoring a need for more services, messages, and access to medications to help them kick the habit, according to a new government report out today. Nearly 69% of adult smokers wanted to quit [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/although-most-smokers-want-to-quit-only-a-fraction-actually-do/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Approves Cetuximab for Late-Stage Head and Neck Cancer</title>
		<link>http://oralcancernews.org/wp/fda-approves-cetuximab-for-late-stage-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/fda-approves-cetuximab-for-late-stage-head-and-neck-cancer/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 18:05:16 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[colon cancer]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[Food and Drug Administration]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[radiation therapy]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12059</guid>
		<description><![CDATA[Source: The Oncology Report The Food and Drug Administration on Nov. 7 approved cetuximab as an initial treatment of late-stage head and neck cancer in combination with chemotherapy. Cetuximab, marketed as Erbitux by Bristol-Myers Squibb, is an epidermal growth factor receptor (EGFR) antagonist, administered as an intravenous infusion. Previously, it was approved in combination with [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/fda-approves-cetuximab-for-late-stage-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

